Objective To analyze the therapeutic effect of butylphthalein softgel combined with rosuvastatin on patients with ischemic stroke. Methods 90 patients with ischemic stroke admitted to our hospital from March 2023 to March 2024 were selected as the study objects. The subjects were divided into control group (n=45) and observation group (n=45) according to random number table method. The control group was treated with rosuvastatin. Observation group was treated with butylphthalein softgel on the basis of control group. The clinical efficacy, neurological function, low density lipoprotein cholesterol (LDL-C) level and adverse reactions of the two groups were analyzed and compared. Results The total effective rate of observation group was significantly higher than that of control group (P < 0.05). After treatment, the NIHSS score and LDL-C level in both groups were significantly lower than before treatment, and the NIHSS score and LDL-C level in the observation group were significantly lower than those in the control group (P < 0.05). There was no significant difference in adverse reactions between the two groups (P > 0.05). Conclusion The combination of buphthalein softgel capsule and rosuvastatin in the treatment of ischemic stroke patients can improve the neurological function, reduce the level of blood lipid, improve the therapeutic effect, and have good safety.